Navigation Links
Pazopanib in Medical News

NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS

Two Phase II studies demonstrated potential for pazopanib as a single agent treatment for early stage non-small cell lung cancer and advanced renal cell cancer: -- In patients with stage I-III non-small cell lung cancer, 86 percent of patients who received pazopanib monotherapy exper...

Drug That Targets Vasculature Growth Attacks Aggressive Thyroid Cancer, Mayo Clinic Researchers Report

...ifferentiated thyroid cancer treated with the drug pazopanib either stopped growing, or quickly shrank. T...d any effective therapies for such patients." pazopanib is an experimental agent that is also being studie...the growth and spread of tumors. The proteins that pazopanib targets include vascular endothelial growth factor...

Drug that targets vasculature growth attacks aggressive thyroid cancer

...ifferentiated thyroid cancer treated with the drug pazopanib either stopped growing, or quickly shrank. The...had any effective therapies for such patients." pazopanib is an experimental agent that is also being studie...the growth and spread of tumors. The proteins that pazopanib targets include vascular endothelial growth factor...

Research Findings on Nine GlaxoSmithKline Cancer Compounds to be Presented at ASCO 2009

...clude First Presentation of Phase III Progression Free Survival Results for pazopanib in Kidney Cancer LONDON and PHILADELPHIA, May 11 /PRNewswire/ -- G... ORAL PRESENTATION: "A randomized, double-blind Phase III study of pazopanib in treatment naive and cytokine-pretreated patients with advanced renal cel...

NYP/Weill Cornell physician-scientists present latest cancer findings at ASCO meeting

...oration with the MD Anderson Cancer Center. Preoperative treatment with pazopanib (GW786034), a multikinase angiogenesis inhibitor in early-stage non-small c...hly effective for the treatment of early-stage non-small cell lung cancer. pazopanib works by blocking the action of vascular endothelial growth factor receptor...

GlaxoSmithKline Presents Innovative Neuroscience Pipeline

... (US) Promacta (hep c) Wellbutrin XR (EU) Rotarix (US) Tykerb (H&N cancer) Tykerb + pazopanib (IBC) Before year-end, GSK will submit a regulatory filing to the FDA for Promacta, its first-in-class,...

Pazopanib Shows Positive in Advanced Renal Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma

...announced results from ongoing Phase II studies of pazopanib in advanced or metastatic renal cell carcinoma (RC...Chicago. The results observed in these trials with pazopanib support further investigations. Pazopanib ...ntaining regimen). All patients received 800 mg of pazopanib taken orally, once-daily during a 12 week lead-in ...
Pazopanib in Medical Technology

GSK'S Pazopanib Shows Positive Results in Patients with Advanced Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma

CHICAGO, June 04, 2007 /PRNewswire/ -- GlaxoSmithKline today announced results from ongoing Phase II studies of pazopanib in advanced or metastatic renal cell carcinoma (RCC), ovarian cancer and soft tissue sarcoma (STS). These trials were presented at the 43rd Annual Meeting of the American Socie...

US Oncology Affiliated Physicians Make a Strong Showing in ASCO Proceedings

...te-resistant prostate cancer (mCRPC)-preliminary results; Biomarker analysis and final results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor; A multicenter, prospective Phase II trial of sorafenib in patients (Pts) with metastatic ...

New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens

...w blood vessels (angiogenesis).(7) Lapatinib and pazopanib in HER2-positive advanced or metastatic breast can...Y, JUNE 1, 2008; 9:30 - 9:45 AM (CDT) TYKERB and pazopanib separately target the HER2 and VEGF pathways. This... 36.2 percent of patients treated with TYKERB plus pazopanib experienced disease progression versus 38.9 percen...

GlaxoSmithKline Reports Further Progress of Oncology Portfolio

...15 am - 9:30 am, E-Hall D1 Randomized study of pazopanib + lapatinib vs. lapatinib alone in patients with H...ults of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitorD...l Cell Lung Cancer Preoperative treatment with pazopanib (GW786034) a multikinase angiogenesis inhibitor in...

New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel

...ne in patients with myelodysplastic syndromes -- Thomas Hutson, D.O., PharmD, Associate Chair, GU Cancer, US Oncology Research: pazopanib (PAZ, GW786034) in pts w/ metastatic Renal Cell Carcinoma (RCC): Interim results of a PH II Randomized Discontinuation Trial (RDT) ...
Pazopanib in Biological Technology

33rd ESMO Congress in Stockholm, 12-16 September 2008

...xamine the benefits of customising lung cancer treatment based on mutations in the epidermal growth factor receptor (EGFR) gene. Phase II trial of pazopanib before surgery in early lung cancer (Embargoed until Monday, 15 September 2008, 10:45 CEST) Pazopanib, a new oral angiogenesis inhibitor, has demo...
Other Tags
(Date:9/17/2014)... (PRWEB) September 17, 2014 In Pretrial ... that “bi-weekly telephonic discovery conferences would be beneficial in ... conferences through mid-December. “At the end of December,” the ... the need for additional conferences. , “The plain ... that there is still much to be discussed as ...
(Date:9/17/2014)... 2014 (HealthDay News) -- Positive messages about the health ... the habit, a new study suggests. Although smokers ... "loss-framed" messages about the harmful effects of smoking, researchers ... want benefit more from "gain-framed," or positive, messages about ... concluded that using a mix of both types of ...
(Date:9/17/2014)... Many countries choose to kill all infected poultry ... number of poultry exceeds 10 billion in China. Epidemic ... huge losses. Therefore, it is quite necessary to immunize ... vaccines have been used for more than 10 years ... use H5N1 avian influenza vaccines voluntarily 10 years ago ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 StartX ... revealed 12 companies raising rounds of funding at its ... few hundred investors and media, was the first such ... located next to the university. The presentations were delivered ... adjacent to StartX-QB3 Labs, a 2,000 square foot life ...
(Date:9/17/2014)... The Delta Dental Community Care Foundation announced today ... Health Foundation: America’s ToothFairy (NCOHF) to support oral health ... Zone Program® in California. , The Orange County NCOHF ... local constituent groups and stakeholders in a comprehensive approach ... its devastating effects on local families. The support of ...
Breaking Medicine News(10 mins):Health News:Transvaginal Mesh Lawsuit News: New Order in C.R. Bard MDL Sets Schedule of Conferences for September to December, the Rottenstein Law Group LLP Reports 2Health News:More Than One Kind of Message May Convince Smokers to Quit, Study Says 2Health News:China Avian Influenza Vaccine Industry 2014-2018 Research Report Now Available at LifeScienceIndustryResearch.com 2Health News:China Avian Influenza Vaccine Industry 2014-2018 Research Report Now Available at LifeScienceIndustryResearch.com 3Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 2Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 3Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 4Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 5Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 6Health News:Delta Dental Community Care Foundation Donation to America's ToothFairy Helps Deliver Critical Services 2
(Date:9/17/2014)... Washington, USA -- "Nature has developed, very cleverly, some ... desire in optical design," said Joseph Shaw, director of ... we explore surfaces and structures at the nanoscale, we,ll ... in San Diego in August during a conference called ... Shaw and Rongguang Liang of the University of Arizona ...
(Date:9/17/2014)... Spanish researchers have obtained the first partial genome sequence ... pig found at the site of the Montsoriu Castle ... pig is closely related to today,s Iberian pig. Researchers ... with modern Iberian pigs. , The study, published in ... of pig species, and particularly on that of the ...
(Date:9/17/2014)... team of researchers working on a Carnegie expedition in ... rates have plummeted 40% since the mid-1970s. The scientists ... role in this perilous slowdown. , In a ... reefs, the team compared current measurements of the growth ... with similar measurements taken more than 30 years ago. ...
Breaking Biology News(10 mins):Nature's designs inspire research into new light-based technologies 2Nature's designs inspire research into new light-based technologies 3Iberian pig genome remains unchanged after 5 centuries 2Coral growth rate plummets in 30-year comparison 2
Other Contents